Enorama Pharma Financials
| ERMA Stock | SEK 3.77 0.09 2.33% |
Enorama |
Understanding current and past Enorama Pharma Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Enorama Pharma's financial statements are interrelated, with each one affecting the others. For example, an increase in Enorama Pharma's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Enorama Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Enorama Pharma AB. Check Enorama Pharma's Beneish M Score to see the likelihood of Enorama Pharma's management manipulating its earnings.
Enorama Pharma Stock Summary
Enorama Pharma competes with Stille AB, Midsona AB, C Rad, and Novotek AB. Enorama Pharma AB , a pharmaceutical company, develops, manufactures, and sells medicated chewing gum containing proven generic substances in Sweden. Enorama Pharma AB is a subsidiary of Swede Unipharma AB. Enorama Pharma is traded on Stockholm Stock Exchange in Sweden.| Instrument | Sweden Stock View All |
| Exchange | Stockholm Exchange |
| ISIN | SE0008216329 |
| Business Address | Vstra Varvsgatan 19, |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Benchmark | Dow Jones Industrial |
| Website | www.enorama.se |
| Phone | 46 7 08 72 82 50 |
| Currency | SEK - Swedish Kronor |
You should never invest in Enorama Pharma without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Enorama Stock, because this is throwing your money away. Analyzing the key information contained in Enorama Pharma's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Enorama Pharma Key Financial Ratios
Enorama Pharma's financial ratios allow both analysts and investors to convert raw data from Enorama Pharma's financial statements into concise, actionable information that can be used to evaluate the performance of Enorama Pharma over time and compare it to other companies across industries.| Return On Equity | -32.88 | |||
| Return On Asset | -0.53 | |||
| Number Of Employees | 10 | |||
| Beta | 1.65 | |||
| Z Score | 31.2 |
Enorama Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Enorama Pharma's current stock value. Our valuation model uses many indicators to compare Enorama Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Enorama Pharma competition to find correlations between indicators driving Enorama Pharma's intrinsic value. More Info.Enorama Pharma AB is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Enorama Pharma's earnings, one of the primary drivers of an investment's value.Enorama Pharma AB Systematic Risk
Enorama Pharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Enorama Pharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on Enorama Pharma AB correlated with the market. If Beta is less than 0 Enorama Pharma generally moves in the opposite direction as compared to the market. If Enorama Pharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Enorama Pharma AB is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Enorama Pharma is generally in the same direction as the market. If Beta > 1 Enorama Pharma moves generally in the same direction as, but more than the movement of the benchmark.
Enorama Pharma November 23, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Enorama Pharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Enorama Pharma AB. We use our internally-developed statistical techniques to arrive at the intrinsic value of Enorama Pharma AB based on widely used predictive technical indicators. In general, we focus on analyzing Enorama Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Enorama Pharma's daily price indicators and compare them against related drivers.
| Information Ratio | (0.09) | |||
| Maximum Drawdown | 27.06 | |||
| Value At Risk | (8.91) | |||
| Potential Upside | 10.4 |
Additional Tools for Enorama Stock Analysis
When running Enorama Pharma's price analysis, check to measure Enorama Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enorama Pharma is operating at the current time. Most of Enorama Pharma's value examination focuses on studying past and present price action to predict the probability of Enorama Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enorama Pharma's price. Additionally, you may evaluate how the addition of Enorama Pharma to your portfolios can decrease your overall portfolio volatility.